A much-needed move by Pfizer

[anonymous]

For a while, Pfizer's been feeling the pinch of Lyrica facing stiff competition..... Now, its going full-throttle on cancer research, the latest move being the buyout of Array Biopharma. While the $11-billion price looks a bit high, the strong pipeline is a wise bet...

 

[anonymous]

For a while, Pfizer's been feeling the pinch of Lyrica facing stiff competition..... Now, its going full-throttle on cancer research, the latest move being the buyout of Array Biopharma. While the $11-billion price looks a bit high, the strong pipeline is a wise bet...

If history repeats itself as it does frequently with Pfizer, it’s a bet you’ll lose.
Pfizer ruins most of what it touches.

 

[anonymous]

If history repeats itself as it does frequently with Pfizer, it’s a bet you’ll lose.
Pfizer ruins most of what it touches.

So true, except for Viagra. It would beat all the stiff competition no matter how ugly Pfizer was.

 

[anonymous]

If history repeats itself as it does frequently with Pfizer, it’s a bet you’ll lose.
Pfizer ruins most of what it touches.

Not true. Array wanted to get bought and they were. They won. On to the next biotech...

 

[anonymous]

So true, except for Viagra. It would beat all the stiff competition no matter how ugly Pfizer was.

LOL